Influence of Transporter Polymorphisms on Drug Disposition and Response: A Perspective From the International Transporter Consortium

被引：88
|
作者：
Yee, Sook Wah [1 ,2 ]
Brackman, Deanna J. [1 ,2 ]
Ennis, Elizabeth A. [1 ,2 ]
Sugiyama, Yuichi [3 ]
Kamdem, Landry K. [4 ]
Blanchard, Rebecca [5 ]
Galetin, Aleksandra [6 ]
Zhang, Lei [7 ]
Giacomini, Kathleen M. [1 ,2 ,8 ]
机构：
[1] Univ Calif San Francisco, Sch Pharm, Dept Bioengn & Therapeut Sci, San Francisco, CA 94143 USA
[2] Univ Calif San Francisco, Sch Med, Dept Bioengn & Therapeut Sci, San Francisco, CA 94143 USA
[3] RIKEN, Res Cluster Innovat, RIKEN Innovat Ctr, Sugiyama Lab, Yokohama, Kanagawa, Japan
[4] Harding Univ, Coll Pharm, Dept Pharmaceut Sci, Searcy, AR USA
[5] CRISPR Therapeut, Cambridge, MA USA
[6] Univ Manchester, Sch Hlth Sci, Ctr Appl Pharmacokinet Res, Manchester, Lancs, England
[7] US FDA, Off Res & Stand, Off Gener Drugs, Ctr Drug Evaluat & Res, Silver Spring, MD USA
[8] Univ Calif San Francisco, Inst Human Genet, San Francisco, CA 94143 USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2018年 / 104卷 / 05期
关键词：
D O I：
10.1002/cpt.1098
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Advances in genomic technologies have led to a wealth of information identifying genetic polymorphisms in membrane transporters, specifically how these polymorphisms affect drug disposition and response. This review describes the current perspective of the International Transporter Consortium(ITC) on clinically important polymorphisms in membrane transporters. ITC suggests that, in addition to previously recommended polymorphisms in ABCG2 (BCRP) and SLCO1B1 (OATP1B1), polymorphisms in the emerging transporter, SLC22A1 (OCT1), be considered during drug development. Collectively, polymorphisms in these transporters are important determinants of interindividual differences in the levels, toxicities, and response to many drugs.
引用
收藏
页码：803 / 817
页数：15
相关论文
共 50 条
  • [41] Genetic polymorphisms of the human MDR1 drug transporter
    Schwab, M
    Eichelbaum, M
    Fromm, MF
    ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 2003, 43 : 285 - 307
  • [42] Polymorphisms in the ABC drug transporter gene MDR1
    Brinkmann U.
    The Pharmacogenomics Journal, 2001, 1 (1) : 59 - 64
  • [43] Impact of genetic polymorphisms of ABC transporter genes on the drug treatment
    Ieiri, I
    JAPANESE JOURNAL OF PHARMACOLOGY, 2002, 88 : 47P - 47P
  • [44] Disease-Associated Changes in Drug Transporters May Impact the Pharmacokinetics and/or Toxicity of Drugs: A White Paper From the International Transporter Consortium
    Evers, Raymond
    Piquette-Miller, Micheline
    Polli, Joseph W.
    Russel, Frans G. M.
    Sprowl, Jason A.
    Tohyama, Kimio
    Ware, Joseph A.
    de Wildt, Saskia N.
    Xie, Wen
    Brouwer, Kim L. R.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2018, 104 (05) : 900 - 915
  • [45] New and Emerging Research on Solute Carrier and ATP Binding Cassette Transporters in Drug Discovery and Development: Outlook from the International Transporter Consortium
    Giacomini, Kathleen M.
    Yee, Sook W.
    Koleske, Megan L.
    Zou, Ling
    Matsson, Par
    Chen, Eugene C.
    Kroetz, Deanna L.
    Miller, Miles A.
    Gozalpour, Elnaz
    Chu, Xiaoyan
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2022, 112 (03) : 540 - 561
  • [46] Perspective on the Application of Microphysiological Systems to Drug Transporter Studies
    Caetano-Pinto, Pedro
    Stahl, Simone H.
    DRUG METABOLISM AND DISPOSITION, 2018, 46 (11) : 1647 - 1657
  • [47] Survey of Pharmaceutical Industry's Best Practices around In Vitro Transporter Assessment and Implications for Drug Development: Considerations from the International Consortium for Innovation and Quality for Pharmaceutical Development Transporter Working Group
    Rollison, Helen E.
    Mitra, Pallabi
    Chanteux, Hugues
    Fang, Zhizhou
    Liang, Xiaomin
    Park, Seong Hee
    Costales, Chester
    Hanna, Imad
    Thakkar, Nilay
    Vergis, James M.
    Bow, Daniel A. J.
    Hillgren, Kathleen M.
    Brumm, Jochen
    Chu, Xiaoyan
    Hop, Cornelis E. C. A.
    Lai, Yurong
    Li, Cindy Yanfei
    Mahar, Kelly M.
    Salphati, Laurent
    Sane, Rucha
    Shen, Hong
    Taskar, Kunal
    Taub, Mitchell
    Tohyama, Kimio
    Xu, Christine
    Fenner, Katherine S.
    DRUG METABOLISM AND DISPOSITION, 2024, 52 (07) : 582 - 596
  • [48] Genetic polymorphisms in human organic cation transporter 1 (OCT1) are determinants of metformin disposition and response.
    Shu, Y.
    Brown, C.
    Owen, R. P.
    Zhang, S.
    Castro, R. A.
    Lin, E. T.
    Lo, J.
    Burchard, E. G.
    Brett, C. M.
    Giacomini, K. M.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2007, 81 : S2 - S2
  • [49] Genetic polymorphisms in human organic cation transporter 1 (OCT1) are determinants of metformin disposition and response.
    Shu, Y.
    Brown, C.
    Owen, R. P.
    Zhang, S.
    Castro, R. A.
    Lin, E. T.
    Lo, J.
    Burchard, E. G.
    Brett, C. M.
    Giacomini, K. M.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2007, 81 : S7 - S8
  • [50] Genetic Variants of the Organic Cation Transporter 2 Influence the Disposition of Metformin
    Song, I. S.
    Shin, H. J.
    Shim, E. J.
    Jung, I. S.
    Kim, W. Y.
    Shon, J. H.
    Shin, J. G.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 84 (05) : 559 - 562
12345